TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19198007

Group type: EXPERIMENTAL
Intervention: Complete embolic protection
Number of subjects: 44

Group type: COMPARATOR
Intervention: Partial embolic protection
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Abciximab in partial protection group
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Abciximab in complete protection group
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Complete protection
Number of subjects: 44
Study: 17889127

Group type: EXPERIMENTAL
Intervention: Cyclosporine microemulsion (CyA)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Tacrolimus (TC)
Number of subjects: 81
Study: 15365919

Group type: EXPERIMENTAL
Intervention: Enoximone, 5 microg/kg/min (group A)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Dobutamine at the same dose (group B)
Number of subjects: 216
Study: 11515819

Group type: EXPERIMENTAL
Intervention: BCG-CWS stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-tumor resection
Number of subjects: 0
Study: 9755346

Group type: EXPERIMENTAL
Intervention: Problem-Solving Training (PST)
Number of subjects: 341

Group type: COMPARATOR
Intervention: General Health Counseling (GHC)
Number of subjects: 341
Study: 9122547

Group type: EXPERIMENTAL
Intervention: Intact milk
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Hydrolyzed milk (> 90% of lactose hydrolyzed)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Hydrolyzed milk
Number of subjects: 25
Study: 2184179

Group type: EXPERIMENTAL
Intervention: Re‐PUVA
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Re
Number of subjects: 20

Group type: COMPARATOR
Intervention: PUVA
Number of subjects: 20
Study: 7268333

Group type: EXPERIMENTAL
Intervention: Björk‐Shiley (B‐S) valves
Number of subjects: 300

Group type: COMPARATOR
Intervention: Lillehei‐Kaster (L‐K) valves
Number of subjects: 300
Study: 29726739

Group type: EXPERIMENTAL
Intervention: 80-mg ixekizumab every 2 weeks (IXEQ2W)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 50 mg etanercept (ETN) biweekly
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 80-mg ixekizumab every 4 weeks (IXEQ4W)
Number of subjects: 0
Study: 28644370

Group type: EXPERIMENTAL
Intervention: New Complementary Feeding Guidelines (NCFg) focusing on meat, fruits, vegetables, and breast milk
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Alternative food-based recommendations (FBRs) promoting legumes, dairy, vitamin A-rich vegetables, and chicken giblets
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Fortified infant food
Number of subjects: 72
Study: 26404200

Group type: EXPERIMENTAL
Intervention: Transfemoral TAVR (TF-TAVR)
Number of subjects: 3013

Group type: EXPERIMENTAL
Intervention: Transapical TAVR (TA-TAVR)
Number of subjects: 3013
Study: 25066921

Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Prolonged Exposure (PE)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 210
Study: 22690320

Group type: EXPERIMENTAL
Intervention: WGOE supplementation (1500 mg/day)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 19304577

Group type: EXPERIMENTAL
Intervention: Loose larvae
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Bagged larvae
Number of subjects: 267

Group type: COMPARATOR
Intervention: Larval therapy (loose or bagged larvae)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Hydrogel
Number of subjects: 267
Study: 17692126

Group type: EXPERIMENTAL
Intervention: Exemestane (25 mg)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 15558649

Group type: EXPERIMENTAL
Intervention: Cognitive dissonance‐based, thin‐ideal internalization, single‐session workshop (DTI; n = 26)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Psychoeducational, healthy behavior, single‐session workshop (HB; n = 24)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Wait-list control (WL; n = 34)
Number of subjects: 84
Study: 11280847

Group type: EXPERIMENTAL
Intervention: Low dose of zidovudine (AZT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High dose of zidovudine (AZT)
Number of subjects: 0
Study: 9004877

Group type: EXPERIMENTAL
Intervention: Tono-Pen
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: ProTon
Number of subjects: 100

Group type: COMPARATOR
Intervention: HAT (Hand-held Applanation Tonometer)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Goldmann tonometer
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tono-Pen I vs II
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: ProTon I vs II
Number of subjects: 100
Study: 1409765

Group type: COMPARATOR
Intervention: Harpagophytum procumbens (Devil's Claw) - 4 capsules of 500 mg powder containing 3% total glucoiridoids daily for 21 days
Number of subjects: 25
Study: 2417351

Group type: EXPERIMENTAL
Intervention: Org 10172 (low molecular weight heparinoid)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Heparin (loading dose 2,500 IU + continuous infusion of 1,800 IU/hr)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both Org 10172 and Heparin
Number of subjects: 55

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Org 10172
Number of subjects: 55
Study: 30937736

Group type: EXPERIMENTAL
Intervention: Function-based behavior analytic interventions delivered via telehealth over 12 weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Parent procedural integrity and acceptability ratings
Number of subjects: 10
Study: 30324927

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Oral dexmedetomidine
Number of subjects: 44
Study: 26398884

Group type: EXPERIMENTAL
Intervention: CT scans assessed by 9 blinded reviewers
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Consensus group discussion of CT scans
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Validation group reassessment of CT scans after consensus group recommendations
Number of subjects: 100

Group type: COMPARATOR
Intervention: Clinical examination vs consensus group assessment of CT scans
Number of subjects: 100
Study: 25105662

Group type: EXPERIMENTAL
Intervention: Aliskiren (300mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Perindopril (10mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 22238392

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/d
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study: 20304883

Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) cardiac troponin I testing
Number of subjects: 80

Group type: COMPARATOR
Intervention: Central laboratory testing
Number of subjects: 80
Study: 17661940

Group type: EXPERIMENTAL
Intervention: High-viscosity 2-octyl cyanoacrylate (HVOCA)
Number of subjects: 14

Group type: COMPARATOR
Intervention: 5-0 polypropylene suture
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: HVOCA
Number of subjects: 14
Study: 16036196

Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine (group A)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo (group B)
Number of subjects: 164
Study: 12235926

Group type: EXPERIMENTAL
Intervention: Dai-kenchu-to (DKT) 15 g orally daily for 14 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 10404578

Group type: EXPERIMENTAL
Intervention: Active capacitively coupled electrical stimulation
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 179
Study: 8665534

Group type: EXPERIMENTAL
Intervention: Entacapone (100-800 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Entacapone (400 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Entacapone (400 mg and 800 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: CR levodopa-carbidopa without entacapone (control treatment)
Number of subjects: 12
Study: 1837161

Group type: EXPERIMENTAL
Intervention: Deep freezing with D.M.S.O. and staged decrease of temperature with immersion into liquid nitrogen
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Immersion into nitrogen without cryoprotection
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Deep freezing in an electric device down to -80 degrees C
Number of subjects: 154

Group type: COMPARATOR
Intervention: Fresh state (standard sample manufacturing)
Number of subjects: 154
Study: 6355798

Group type: EXPERIMENTAL
Intervention: Hypertransfusion (red cell transfusion to a hemoglobin value ≥ 17 gm/dl prior to each chemotherapy cycle)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (no hypertransfusion)
Number of subjects: 25
Study: 30577901

Group type: EXPERIMENTAL
Intervention: Recovery Line (RL) + Treatment-as-Usual (TAU)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Treatment-as-Usual (TAU)
Number of subjects: 82
Study: 29929861

Group type: EXPERIMENTAL
Intervention: ypT0 carcinoma
Number of subjects: 776

Group type: EXPERIMENTAL
Intervention: ypT1 carcinoma
Number of subjects: 776

Group type: EXPERIMENTAL
Intervention: ypT2 carcinoma
Number of subjects: 776

Group type: EXPERIMENTAL
Intervention: Advanced ypT category
Number of subjects: 776

Group type: EXPERIMENTAL
Intervention: Lymphatic invasion
Number of subjects: 776

Group type: EXPERIMENTAL
Intervention: RTD ≥10 mm
Number of subjects: 776
Study: 26724671

Group type: EXPERIMENTAL
Intervention: Reduced dose X-ray examination (3.06 μSv)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Standard dose X-ray examination (4.57 μSv)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Evaluation of defined criteria (dose-independent)
Number of subjects: 264
Study: 24157241

Group type: EXPERIMENTAL
Intervention: Wearing a helmet
Number of subjects: 19

Group type: COMPARATOR
Intervention: No helmet
Number of subjects: 19
Study: 21994078

Group type: EXPERIMENTAL
Intervention: Single-port laparoscopic procedure
Number of subjects: 13

Group type: COMPARATOR
Intervention: Three-port laparoscopic procedure
Number of subjects: 13
Study: 19056034

Group type: EXPERIMENTAL
Intervention: RBCs stored no longer than 7 days
Number of subjects: 450

Group type: COMPARATOR
Intervention: Standard practice (RBCs stored longer than 7 days)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 450
Study: 17995495

Group type: EXPERIMENTAL
Intervention: Levonorgestrel intrauterine system (LNG‐IUS)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group (no LNG‐IUS)
Number of subjects: 113
Study: 16699904

Group type: EXPERIMENTAL
Intervention: Efalizumab 1 mg/kg/wk
Number of subjects: 1651

Group type: EXPERIMENTAL
Intervention: Efalizumab 2 mg/kg/wk
Number of subjects: 1651

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1651

Group type: EXPERIMENTAL
Intervention: Efalizumab
Number of subjects: 1651
Study: 11752040

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 23

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both tacrolimus and cyclosporine
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Tacrolimus and Cyclosporine
Number of subjects: 23
Study: 9883710

Group type: EXPERIMENTAL
Intervention: Combination therapy of valsartan (80 mg or 160 mg) and HCTZ (12.5 mg or 25 mg)
Number of subjects: 871

Group type: EXPERIMENTAL
Intervention: Valsartan (80 mg or 160 mg) alone
Number of subjects: 871

Group type: EXPERIMENTAL
Intervention: HCTZ (12.5 mg or 25 mg) alone
Number of subjects: 871

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 871
Study: 7976233

Group type: EXPERIMENTAL
Intervention: Tolfenamic acid 100 mg three times daily
Number of subjects: 76

Group type: COMPARATOR
Intervention: Propranolol 40 mg three times daily
Number of subjects: 76
Study: 2968266

Group type: EXPERIMENTAL
Intervention: Percutaneous 17 beta‐oestradiol combined with progesterone (n = 29)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Oral oestradiol valerate combined with cyproterone acetate (n = 37)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: 24R, 25 (OH)2D3 (n = 29)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Placebo (n = 28)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Placebo (n = 39)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Placebo (n = 29)
Number of subjects: 191
Study: 31789303

Group type: EXPERIMENTAL
Intervention: Comprehensive nursing based on feedforward control
Number of subjects: 114

Group type: COMPARATOR
Intervention: Conventional nursing
Number of subjects: 114
Study: 28372315

Group type: EXPERIMENTAL
Intervention: Heavy back squat (90-95% of one repetition maximum)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Moderate-intensity back squat (60-65% of one repetition maximum)
Number of subjects: 22
Study: 25811573

Group type: EXPERIMENTAL
Intervention: Silicone gel sheets for 2 months
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Silicone gel sheets for 6 months
Number of subjects: 36

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 36
Study: 22672255

Group type: EXPERIMENTAL
Intervention: Tissue Doppler Imaging (TDI) derived Myocardial Performance Index of Right Ventricle (MPI-RV)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Tissue Doppler Imaging (TDI)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Pulmonary hypertension detection
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Correlation analysis of MPI-RV with pulmonary artery pressures and left ventricular ejection fraction
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Comparison of MPI-RV in ESRD patients with and without pulmonary hypertension
Number of subjects: 41
Study: 20441516

Group type: EXPERIMENTAL
Intervention: Albendazole treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18807678

Group type: EXPERIMENTAL
Intervention: Prothrombin complex concentrate (Proplex T)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (Vitamin K and fresh-frozen plasma)
Number of subjects: 0
Study: 16191080

Group type: EXPERIMENTAL
Intervention: Bicarbonate dialysis
Number of subjects: 35

Group type: COMPARATOR
Intervention: Acetate dialysis
Number of subjects: 35
Study: 12011552

Group type: EXPERIMENTAL
Intervention: Short (3-day) hospitalization followed by home care treatment
Number of subjects: 102

Group type: COMPARATOR
Intervention: Conventional (10-day) hospitalization
Number of subjects: 102
Study: 10380161

Group type: EXPERIMENTAL
Intervention: 2.0 ppm NO2
Number of subjects: 8

Group type: COMPARATOR
Intervention: Filtered air (control)
Number of subjects: 8
Study: 7776711

Group type: EXPERIMENTAL
Intervention: 3,4-diaminopyridine (3,4-DAP) at stepped doses increasing to 20 mg four times daily for 4 days
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 2185967

Group type: EXPERIMENTAL
Intervention: Octreotide infusion (25 micrograms/h)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Octreotide infusion (25 micrograms/h for 48 h)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: COMPARATOR
Intervention: Oesophageal tamponade
Number of subjects: 56
Study: 6786091

Group type: EXPERIMENTAL
Intervention: Pneumatic dilation (4-4.5 kg./6.5 cm.2 x 2 min.)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Bouginage (44-55 ff catheter)
Number of subjects: 18
Study: 31519347

Group type: EXPERIMENTAL
Intervention: Standard Patients (SPs) usage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (theoretical lecture)
Number of subjects: 0
Study: 28624914

Group type: EXPERIMENTAL
Intervention: SRP plus desiccant (Hybenx®)
Number of subjects: 36
Study: 26786905

Group type: EXPERIMENTAL
Intervention: Family‐Based Cognitive‐Behavioral Social Work (FBCBSW) intervention
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 27
Study: 25157535

Group type: EXPERIMENTAL
Intervention: fMRI sessions (2 sessions, each lasting 1.5 hours)
Number of subjects: 9
Study: 23063168

Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin for 6 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 80
Study: 20139236

Group type: EXPERIMENTAL
Intervention: Disinfection by-products (DBPs) exposure in drinking water
Number of subjects: 13
Study: 18344439

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents
Number of subjects: 826

Group type: COMPARATOR
Intervention: Bare metal stents
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Patients with target-vessel ischemia
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Target-vessel ischemia
Number of subjects: 826
Study: 15800310

Group type: EXPERIMENTAL
Intervention: UFT (uracil and tegafur)
Number of subjects: 2934

Group type: EXPERIMENTAL
Intervention: TAM (tamoxifen)
Number of subjects: 2934

Group type: COMPARATOR
Intervention: Control (no adjuvant therapy)
Number of subjects: 2934
Study: 12452224

Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Regional anesthesia
Number of subjects: 120

Group type: COMPARATOR
Intervention: Age group (≥60 years)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Age group (<60 years)
Number of subjects: 120
Study: 10506720

Group type: EXPERIMENTAL
Intervention: Carbogen inhalation alone
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Carbogen inhalation with oral nicotinamide (80 mg/kg)
Number of subjects: 61
Study: 7554702

Group type: EXPERIMENTAL
Intervention: Alendronate (5 to 80 mg) taken with water in the fasting state
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Alendronate taken 60 or 30 minutes before a standardized breakfast
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Alendronate taken concurrently with or 2 hours after breakfast
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Alendronate taken with black coffee or orange juice
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Alendronate with ranitidine infusion to increase gastric pH
Number of subjects: 1
Study: 2249704

Group type: EXPERIMENTAL
Intervention: Short version of the prereferral intervention (n = 24)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Long version of the prereferral intervention (n = 24)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (n = 12)
Number of subjects: 60
Study: 6786094

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31477085

Group type: EXPERIMENTAL
Intervention: Hypocaloric low glycemic index (LGI) diet for 24 weeks
Number of subjects: 62
Study: 28291178

Group type: EXPERIMENTAL
Intervention: HYA‐JOINT Plus (3 mL, 20 mg/mL)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Synvisc‐One (6 mL, 8 mg/mL)
Number of subjects: 132
Study: 25644634

Group type: EXPERIMENTAL
Intervention: Stabilisation splint treatment with counselling and masticatory muscle exercises
Number of subjects: 80

Group type: COMPARATOR
Intervention: Counselling and masticatory muscle exercises (Control)
Number of subjects: 80
Study: 24252703

Group type: EXPERIMENTAL
Intervention: AS03A-adjuvanted vaccine (3.75 μg hemagglutinin)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: AS03B-adjuvanted vaccine (1.9 μg hemagglutinin, one or two doses)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Non-adjuvanted 15 μg HA pandemic vaccine
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: All vaccines
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted vaccines
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: All study vaccines
Number of subjects: 310
Study: 21184272

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/day (n=21)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day (n=16)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo (n=20)
Number of subjects: 57
Study: 19864101

Group type: EXPERIMENTAL
Intervention: Structural-enhancement (SE) function used during video colonoscopy
Number of subjects: 593

Group type: COMPARATOR
Intervention: Standard video colonoscopy without SE function
Number of subjects: 593
Study: 18199893

Group type: EXPERIMENTAL
Intervention: Piperaquine phosphate 500 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Piperaquine phosphate 750 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Piperaquine phosphate 1000 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Piperaquine phosphate 1250 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Piperaquine phosphate 1500 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Piperaquine phosphate (multiple doses) 500 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Piperaquine phosphate (multiple doses) 750 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Piperaquine phosphate (multiple doses) 1000 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Piperaquine phosphate (multiple doses) 1500 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15630030

Group type: EXPERIMENTAL
Intervention: Dual-chamber pacing
Number of subjects: 2010
Study: 11969278

Group type: EXPERIMENTAL
Intervention: Direct stenting
Number of subjects: 416

Group type: COMPARATOR
Intervention: Pre-dilated stenting
Number of subjects: 416
Study: 10587839

Group type: EXPERIMENTAL
Intervention: Ethanol infusion (4.35 mmol.kg‐1.h‐1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (saline) infusion
Number of subjects: 10
Study: 8539159

Group type: EXPERIMENTAL
Intervention: DDI (reference pacing mode)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: DDD/AMC (automatic mode conversion)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: DDD/AMC+acc
Number of subjects: 20

Group type: COMPARATOR
Intervention: OOO (CSM without pacing)
Number of subjects: 20
Study: 2294326

Group type: EXPERIMENTAL
Intervention: Consultation by a geriatric assessment team
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Consultation by a 'second opinion' internist
Number of subjects: 600

Group type: COMPARATOR
Intervention: Traditional health maintenance organization services
Number of subjects: 600
Study: 307732

Group type: EXPERIMENTAL
Intervention: 25-hydroxycholecalciferol
Number of subjects: 2

Group type: COMPARATOR
Intervention: Vitamin D2
Number of subjects: 2
Study: 31769181

Group type: EXPERIMENTAL
Intervention: Nurse-led self-management program
Number of subjects: 154